Posted by Michael Wonder on 26 Sep 2022
Santen and UBE received FDA approval for Omlonti (omidenepag isopropyl 0.002% ophthalmic solution) for the reduction of elevated intra-ocular pressure in patients with primary open-angle glaucoma or ocular hypertension
26 September 2022 - Omlonti is the second FDA approved product from Santen in the last 15 months for patients in the US with vision conditions.
Santen and UBE Corporation today announced that the US FDA has approved Omlonti (omidenepag isopropyl ophthalmic solution) 0.002% eye drops for the reduction of elevated intra-ocular pressure in patients with primary open-angle glaucoma or ocular hypertension.
